|
 |
Cutaneous T-Cell LymphomaThis page contains recent news articles, when available, and an overview of Cutaneous T-Cell Lymphoma but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.News: Cutaneous T-Cell Lymphoma PR Newswire (press release)...systemic treatment option for patients with mycosis fungoides and Sezary syndrome, two of the most common types of cutaneous T-cell lymphoma (CTCL). ... Range of Cancer-Fighting Agents Get FDA Nod - 23 Nov 2009 Oncology Nursing NewsIstodax (romidepsin) has been granted approval for use in patients for the treatment of cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior ... Istodax Approved for Cutaneous T-Cell Lymphoma - Nov 6, 2009 U.S. News & World Report...to treat cutaneous T-cell lymphoma (CTCL) in people who have tried at least one prior systemic therapy, the drug's manufacturer said in a news release. ... FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma - Nov 12, 2009 Medical News TodayThe US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma ... FDA Approves ISTODAX For Lymphoma - Nov 9, 2009 Drug Discovery & Development...approved ISTODAX (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. ... Allos Therapeutics, Inc., Q3 2009 Earnings Call Transcript - Nov 3, 2009 Seeking Alpha (blog)To date FOLOTYN has demonstrated encouraging clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma, non-Hodgkin's lymphoma, ... FDA Update - Nov 17, 2009 National Cancer Institute - NCI Cancer BulletinThe FDA has approved the drug romidepsin (Istodax) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare cancer with about 1500 new cases diagnosed ... BioCryst $49M Public Offering Cashes in on Stock Momentum - Nov 20, 2009 BioWorld OnlineFodosine is being studied in a pivotal single-arm Phase II trial under a special protocol assessment for cutaneous T-cell lymphoma. ... CityTech Releases New Web Application to Securely Manage Confidential Medical ... - Nov 18, 2009 Earthtimes (press release)...confidential patient data from the Northwestern Medical Faculty Foundation (NMFF) Department of Dermatology's Cutaneous T-Cell Lymphoma (CTCL) Clinic. ... Leukonychia Related to Vorinostat - Nov 16, 2009 Archives of DermatologyPhase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. ... Therapeutics, - Allos Therapeutics Announces New Data on FOLOTYNâ„¢ to be ... - Nov 11, 2009 Ad-Hoc-News (Pressemitteilung)Pralatrexate is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial? First Author: Steven M. Horwitz, MD, ... BioCryst Receives First Peramivir Order From U.S. Government - Nov 5, 2009 Reuters...peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). ... Affable local chosen for RI Hall of Fame - Nov 17, 2009 The News-PressSt. Martin was diagnosed in March 2007 with cutaneous T-cell lymphoma, a rare form of cancer that usually presents in the skin but is not a skin cancer. ... BioCryst to Present at Oppenheimer Healthcare Conference - Oct 29, 2009 Reuters...peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). ... Genmab Still Cutting: 300 Jobs and Manufacturing Next to Go - Nov 6, 2009 Therapeutics Daily (press release) (registration)Meanwhile Genmab's third antibody, zanolimumab, was dropped last year due to increasing competition in the cutaneous T-cell lymphoma space. ... Eisai and Quintiles to Jointly Develop Six Eisai Anticancer Agents - Oct 30, 2009 Genetic Engineering News (press release)The deal covers Ontak®, which was recently granted FDA approval for the treatment of cutaneous T-cell lymphoma. Also included is eribulin mesylate (E7389), ... Teva broadens suit against Copaxone copycats; Enzon sells marketed meds for $300M; - Nov 10, 2009 FiercePharmaReport > Gloucester Pharmaceuticals got the FDA nod for Istodax, a treatment for a rare form of cancer known as Cutaneous T-cell Lymphoma. ... Investors snap up IMS Health for $5.2B; Amgen cancer med fails to boost ... - Nov 6, 2009 FiercePharmaReport > Gloucester Pharmaceuticals said yesterday that the FDA has approved its lead drug Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL), ... Ironwood Nabs $75M in Deal With Japanese Firm, Gloucester Drug Gets FDA ... - Nov 12, 2009 Xconomy...—Cambridge, MA-based Gloucester Pharmaceuticals won FDA approval for romidepsin (Istodax), a treatment for a rare cancer called cutaneous T-cell lymphoma. ... New College student puts accent on undergraduate research to help fight cancer - Nov 3, 2009 Arizona State University...or alleviating altogether the side effects of Bexarotene, a secondary medication used to treat patients suffering from Cutaneous T-cell Lymphoma (CTCL). ... US FDA approves Istodax to treat rare form of cancer - Nov 11, 2009 pharmabiz.comCutaneous T-cell lymphoma is a slow-growing cancer of infection-fighting white blood cells called T-lymphocytes. Most cases start with dry skin, red rash, ... biocryst Announces Pricing of Public Offering of Common Stock - Nov 22, 2009 PR-CANADA.net (press release)...peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). ... Our Members Know First!! BOFL,AGYS,MBCI,BCRX,BCSI,BNVI - Nov 6, 2009 TMCnet...peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). ... BioCryst Announces Proposed Public Offering of Common Stock - Nov 17, 2009 FOXBusiness...peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). ... "Cutaneous T-Cell Lymphoma": Cutaneous TNMania in Cutaneous Lymphomas - Jul 20, 2009 Archives of DermatologyIn the recent consensus statement on granulomatous mycosis fungoides and granulomatous slack skin (GSS), 1 there was a misuse of the TNM staging terminology On the Trail of a New Killer - Jul 20, 2009 Archives of Dermatology7 The pluripotent progenitor stem-cell theory of carcinogenesis, which has been proposed for several malignancies, including cutaneous T-cell lymphoma Efalizumab and Progression of Undiagnosed Follicular Mycosis ... - Jul 20, 2009 Archives of DermatologyWe respectfully disagree with Di Lernia's comment that patients with pilar MF, F-MF, or folliculotropic cutaneous T-cell lymphoma (CTCL) "should always be BioCryst Reports Second Quarter 2009 Financial Results And ... - Jul 30, 2009 PharmaLive.com (press release) (press release)Forodesine Program -- BioCryst has enrolled more than 100 patients in the pivotal Phase 2 study of forodesine for the treatment of cutaneous T-cell lymphoma PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts ... - Jul 28, 2009 Trading Markets (press release)...peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Vorinostat in solid and hematologic malignancies - Jul 27, 2009 7thSpace Interactive (press release)...and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial ... - Jul 28, 2009 PR Newswire (press release)...peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Honour them before death - Jul 13, 2009 The New Nation...that are regarded as essential guidelines for the local apparel sector, is now suffering from a severe form of skin cancer Cutaneous T-Cell Lymphoma. HDAC Inhibitors: emerging drugs in oncology and other indications - Jul 12, 2009 PipelineReview.com (press release)...generation of pan-HDAC inhibitor produced clinical benefit and the first representative of this class is already marketed for cutaneous T-cell lymphoma. EP, FORM, WIT, AHT, BCPC, BCRX Expected To Be Lower Leading Up To ... - Jul 14, 2009 TMC Net...trial for patients with Cutaneous T-cell Lymphoma (CTCL); and in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Some stocks may cash in on swine flu; BCRX, HEB, NVAX, BTAHY - Jul 22, 2009 Learning MarketsThe company also has a lead oncology drug candidate -- Fodosine, a treatment of cutaneous T-cell lymphoma, which is under a pivotal trial. Romidepsin Active for Treatment of Refractory Cutaneous T-Cell ... - Dec 17, 2008 Cancer Consultants,Clinically significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: Final results from a phase 2B, multicenter, Gloucester Pharmaceuticals Announces Positive Results from ... - Dec 8, 2008 MarketWatchGloucester Pharmaceuticals today announced positive results from the Company's registration trial in cutaneous T-cell lymphoma (CTCL) and from a Phase 2 BioCryst Pharmaceuticals Continues Forodesine HCl Program in ... - Dec 27, 2008 PR-CANADA.net (press release),The drug is currently being studied in clinical trials for indications including T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma Gloucester Pharmaceuticals Announces Positive Results from Phase 1 ... - Dec 9, 2008 MarketWatchAdditional positive data from a single-agent registration study in cutaneous T-cell lymphoma (CTCL) and from a Phase 2 study in CTCL and peripheral T-cell Allos Therapeutics Reveals Positive Results From Two Pralatrexate ... - Dec 6, 2008 RTT News,...includes interim data from a Phase 1 trial of pralatrexate as a single agent in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). BioCryst Pharmaceuticals Elects Stanley C. Erck to its Board of ... - Dec 23, 2008 PR Newswire (press release),...that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of Combination Cancer Therapy is Focus of $1M Merck Research Grant ... - Dec 2, 2008 Business Wire (press release),Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the HDIs and oncology’s great hope - Dec 9, 2008 Australian Life Scientist,The US Food and Drug Administration has already approved the first HDI, Merck’s Vorinostat, as a treatment for cutaneous T-cell lymphoma. German Gov’t Grants Cellzome $4.9M to - Dec 4, 2008 Proteo Monitor,...it developed Zolinza, which was approved in the US in 2006 as a treatment for relapsed or refractory cutaneous T-cell lymphoma, a kind of skin cancer. More than 200 abstracts at ASH and SABCS reveal potential ... - Dec 3, 2008 Trading Markets (press release),...including acute myeloid leukemia, cutaneous t-cell lymphoma, multiple myeloma and mantle cell lymphoma * New data, presented in an oral session, Narrow-band ultraviolet B phototherapy for early stage mycosis ... - Dec 3, 2008 John Libbey Eurotext,1 Bunn PJ, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 1979; 63: 725-8. Curse Of the Lost Compounds - Dec 4, 2008 Corante,Merck signed up to do the clinical and regulatory lifting on this one, and it's now marketed for cutaneous T-cell lymphoma. New data on ZOLINZA (vorinostat) in combination with Bortezomib - Dec 10, 2008 News-Medical.net,ZOLINZA is approved in the United States for treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, MD Anderson to hold first international conference on inflammatory ... - Dec 5, 2008 EurekAlert (press release),...another examines the use of vorinostat, a drug commonly used to treat cutaneous T-cell lymphoma, to treat the aggressive cases of IBC that recur on the Mesothelioma & Asbestos Awareness Center Acknowledges - Dec 2, 2008 TransWorldNews (press release),Vorinostat is a type of histone deacetylase inhibitor that is typically given to patients with cutaneous T-cell lymphoma who have not responded positively Market Report -- In Play (ALTH) - Dec 7, 2008 MSN MoneyOne poster reports interim data from a Phase 1 trial of pralatrexate as a single agent in patients with relapsed or refractory cutaneous T-cell lymphoma. Background information on Cutaneous T-Cell Lymphoma [When available] Cutaneous T-Cell lymphoma (CTCL) is a class of non-Hodgkin's lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin's lymphomas (which are generally B-cell related), CTCL is caused by a mutation of T cells. The malignant T cells in the body are pushed to the surface of the skin in a biological process used to rid the body of offending material, causing various lesions to appear on the skin. These lesions change shape as the disease progresses, typically beginning as what appears to be a rash and eventually forming plaques and tumors before metastatizing to other parts of the body. Though there are many types of CTCL and presentation can vary from individual to individual, there are two main forms: mycosis fungoides (MF) and S�zary syndrome (SS). There is some dispute over whether SS is an advanced form of MF or a different type of CTCL entirely -- in either case, the prognosis for SS patients is substantially poorer than for those of MF. There is no cure for CTCL, but there are a variety of treatment options available and most (about 90%) of CTCL patients are able to live relatively normal lives without serious, health-compromising complications. Search the web for more resources on Cutaneous T-Cell Lymphoma |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
